Successful End-Of-Phase-2 consultations for DeOvo

The anti-lice product DeOvo, developed by Hatchtech Pty Ltd, has successfully completed its end-of-phase II consultations with the FDA.

Following the completion of the phase IIb clinical trial, the FDA has reviewed the current data on DeOvo, as well as the relevant plans and protocols for Phase III trials and given the go-ahead for the Phase III trials, expected to commence later this year.

Hatchtech recently announced a new round of funding for the Phase III trials and are aiming to complete a New Drug Application filing in 2014.